Kanjinti vs herceptin

The 12-month follow-up treatment with Kanjinti [demonstrated] an acceptable cardiac safety profile. In cases where there was a switch from Herceptin to Kanjinti or Kanjinti combined with pertuzumab, the safety profile was similar to that previously reported in other studies, investigators said.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KANJINTI safely and effectively. See full prescribing information for KANJINTI. KANJINTI (trastuzumab-anns) for injection, for intravenous use Initial U.S. Approval: 2024 KANJINTI (trastuzumab-anns) is biosimilar to HERCEPTIN (trastuzumab)

Both Herceptin and Kanjinti are trade names. The chemical names are trastuzumab (Herceptin) and trastuzumab-anns (Kanjinti) indicating Kanjinti

Trastuzumab (Herceptin) is an example of one of these. Other medicines used for targeted therapy include trastuzumab-anns (Kanjinti)

KANJINTI/ KANJINTI, and HERCEPTIN/ HERCEPTIN treatment groups, respectively. trastuzumab 1year vs. observation. The interval represents the

Laboratory studies comparing Kanjinti with Herceptin have shown that the active substance in Kanjinti is highly similar to that in Herceptin in terms of

vial; added Herceptin biosimilar, Kanjinti; Herceptin product availability for multi-dose vial corrected from 420 mg to 440 mg; references updated; newly

KANJINTI (trastuzumab-anns) is biosimilar to HERCEPTIN trastuzumab plus chemotherapy as compared to chemotherapy alone: fatigue (29.5% vs.

Drugs Comparison (Drug Vs. Drug) Vitamins Supplements Drug 420mg/multidose vial (Herceptin, Ogivri, Herzuma, Trazimera, Kanjinti, Ontruzant).